Sensors and robotics are two exponential technologies that will disrupt a multitude of billion-dollar industries.
This post (part 3 of 4) is a quick look at how three industries — transportation, agriculture, and healthcare/elder care — will change this decade.
Before I dive into each of these industries, it’s important I mention that it’s the explosion of sensors that is fundamentally enabling much of what I describe below.
Aubrey de Grey wants to save lives. He wants to save as many as he possibly can, as soon as he can, and to do it he is going to fix ageing.
The prominent scientist and futurologist is on a crusade to beat ageing and when he does it will mean that we stay healthy and live longer – possibly for up to hundreds of years.
But, as de Grey emphasises, his primary goal is not just making people live longer; he wants us to live healthily, he wants to restore us to a state of health that is “fully functional in every way”. The ability to live for hundreds of years is just a side effect.
Not everyone wants to sleep in. A growing transhumanism community wants to sleep less, and better, and they’re going to great lengths to make it happen.
For those unaware, transhumanism is an intellectual and cultural movement that aims to improve the human condition, to push beyond our biological limitations, largely through technological advancements. They’re particularly focused on extreme longevity. But with treatments for an extended healthy life still works in progress (and playing out on a very long timeline), some transhumanists have turned their attention to sleep.
The average well-rested person sleeps eight hours a day. The average American lives 79 years. That’s a little more than just 50 years being awake. Life is much shorter than you realized — at least if you agree with your typical sleep-hacker that sleeping is wasted downtime.
Our gut and the microbiome play a crucial role in our health, but could better understanding of that role help us avoid disease and live longer?
The microbiome weighs 2–3 pounds and contains 10 times more cells than our own, but we’ve neglected our microbial tenants for a long time. These little denizens help us break down food, provide key nutrients and even play a role in inflammation and the integrity of our intestinal tract. It’s no surprise then that fermented foods and probiotics are gaining popularity as we become more aware of how important our gut is. Recent evidence even links poor digestive health to chronic inflammation and Parkinson’s disease.
New research suggests that both gut integrity, and the amount and type of bacteria that reside within it, can actually predict an individual’s health. They may even quicken or slow the pace of aging.
Progress always seems to ride a slippery slope. Innovations generally bring a plethora of potential benefits and just as many dangers, the obvious and the hidden. Technologies that tamper with our biological constructs is well underway in the neuro- and biotech industries. Historically, innovations in medicine have usually been beneficial on the aggregate.
But these new breakthroughs go beyond preventing and healing pre-existing causes. Transhuman technologies hold the promise of enhancing who we are as individuals and potentially as an entire species, and the decisions surrounding these technologies are far from simple. Dr. Nayef Al-Rodhan, a philosopher, neuroscientist, and director of the Geneva Center for Security Policy, believes we should be acting now to prepare for the inevitable and the unpredictable ramifications.
Considering our mixed track record as a species in rolling out groundbreaking innovations, discussing and finding potential solutions to many of the hidden dangers, and obvious ones, seems more than reasonable. One of the more puzzling questions is, where do we begin to have a pragmatic conversation on the ethics of these technologies?
There are plenty of theories about what drive human decisions, not least because human morality is infinitely complex and our minds crave frames through which to make sense of chaos. Dr. Al-Rodhan has his own conception of what drives human motivations. He makes meaning using the lens of “5 P’s” – Power, Pride, Profit, Pleasure, and Permanence – which he posits drive human motivations. “This is my view, the foundation of my outlook…this perceived emotion of self interest drives our moral compass.”
Al-Rodhan’s view of human nature seems to make a lot of sense, bridging the rational with the emotional. Such a frame is particularly helpful when considering technology that undoubtedly taps into our deepest fears and hopes, and invokes rational (and irrational) debate. During a recent TechEmergence interview with Nayef, I asked for his thoughts on the concerns and considerations of this brand of technology in the coming decade.
Al-Rodhan believes that we will see cognitive enhancement primarily through neuropharmacology, or neuro- and psychostimulants. This concept of this technology is nothing new — the military and many other organization have used their stimulants of choice in the past, one of the most pervasive being alcohol. But this new wave of neuro- and psychostimulants will methodically target specific areas in the brain, giving way to the possibility for innovations like increased mood modulation and more cognitive ability within the confines of the brain’s neuronal population.
Neuromodulation has been used in the military, with some efforts to make soldiers less emotional and to require less sleep. The difficulties with side effects are often more pronounced when soldiers return from combat. “They are all messed up due to severe brutality, fear, and some of these agents they are given make them addicts to certain things,” says Nayef, acknowledging that this happens in most all militaries. “The point is that psychostimulants and neuromodulators will make us feel very good, but they are very dangerous because they require addictive behavior…and we need strict oversight mechanisms.”
Nayef says that technologies such as brain machine interface (BMI) are likely beyond the span of a decade, but that implantable microchips (whether bio or biotechnological) are as much of an immediate concern as the introduction of neurostimulants. “The FDA in the United States is entrusted with keeping us on the right path,” says Al-Rodhan.
Finding Common Regulatory Ground
Is it possible to put in place national or international structures for managing these new and emerging technologies? Al-Rodhan believes it is more than possible; however, the primary issue is that our regulation is way behind innovation. Regulatory frameworks are lacking for a number of reasons. The unpopularity in politics is a major obstacle to overcome. In elections, these types of contradictory frameworks are not politically on the front burner for most candidates, and the long-term outlook is limited.
Another area for concern is corporate pharmaceutical entities, which Nayef says are not as well regulated as some might think. Businesses are concerned about the bottom line above all else, which at times yields unfortunate outcomes for the whole of society. “This is part of their role as executive, they’re not too concerned about moral regulation,” says Nayef. As unappealing as it might sound to free market capitalists, the institution that traditionally steps into these frontiers to regulate is government.
A relevant and current example is the science and business of moderating genomes in China, which is already investing a lot of money in this industry. Some effects of this technology may not be so obvious at first, and it is possible that negative ramifications could occur without the correct bioethical oversight. Al-Rodhan asks “what happens if you get a piece of DNA that preludes the biosphere? Who knows what kind of mutation that may produce spontaneously or by merging with other DNA in an organism.” These are the types of questions that governments, academic institutions, corporations, and individual citizens need to be asking, considering the multiple perspectives that emerge from a framework like Al-Rodhan’s that applies across cultural boundaries.
Al-Rodhan describes the process of implementing such regulatory frameworks as a transnational effort, but says that such efforts start with countries like the U.S., Japan, and Europe, where accountable mechanisms already exist. Taking the lead doesn’t guarantee the same priorities will be given elsewhere, but it can provide an example — and ideally a positive one. “We have about a decade to get our act together,” says Al-Rodhan.
Dr Michael Fossel is a PhD and MD heading up telomerase research and therapy and has kindly written a blog article for Bioviva detailing the work both they and his company Telocyte are doing to fight back against Alzheimer’s.
How Alzheimer’s Can Be Prevented and Cured…
Michael Fossel, MD, PhD
As I said in my medical textbook on aging, “If age is a thief, then the greatest treasure we lose is ourselves.” We fear Alzheimer’s not simply because it takes away our health, but because it steals our souls.
Once, we thought it was simply “old age” that gradually killed the cells that carry information and memory. These are brain cells that make us who we are and define our consciousness.
Only in the past two decades, have we gradually come to realize that it’s not the neurons, which are merely the innocent bystanders in the tragedy,
but the microglial cells that cause the disease. It’s our microglia, not our neurons that steal our very souls.
Everything starts to go downhill as we get older and muscle is no exception; even simple tasks become challenging as we lose bone and muscle. Now research has identified a protein behind this age-related decline and therapeutic molecules that can fight it, helping individuals stay healthy and strong for longer.
A team at the Univesity of Iowa has discovered that a protein called ATF4 might be behind muscular decline. ATF 4 is a transcription factor, which means it tells the body to activate or regulate certain genes. ATF4 seems to change skeletal muscle with age, reducing protein synthesis and overall mass.
”Many of us know from our own experiences that muscle weakness and atrophy are big problems as we become older”
What can we do about it?
Researchers also identified two molecules that dramatically reduce this age-related decline in mice: ursolic acid from apple peels, and tomatidine, present in green tomatoes. When elderly mice were fed either of these compounds, muscle mass was increased by 10% and muscle strength by 30% — essentially restoring their muscles to a youthful state.
Sure, it can beat Ken Jennings at Jeopardy, tell you about your city, and dream up recipes for delectable delicacies, but now, IBM’s Watson is doing something even more important than all previous capabilities combined — it’s finally getting closer to becoming your doctor. Last April, the century-old company launched IBM Watson Health, and now, it’s opened up a new office in Cambridge, Massachusetts, home to some of the best universities in the U.S., and some of the most impressive biotech and pharmaceutical companies as well. In the last few months, Watson has already expanded its scope to take on some of our most pressing health issues and diseases, including cancer and diabetes, and with this new establishment, it seems that the supercomputer will only be taking on greater responsibilities in the industry.
More exciting still is the announcement that Deborah DiSanzo, the former CEO of Philips Healthcare, will be leading the unit as its general manager. Under her leadership, IBM hopes that Watson Health will be able to grow and further expand its massive cloud computing capabilities, which the company believes holds significant potential for modern health care. While current “health record systems can do great job storing data,” Mike Rhodin, senior vice president of the IBM Watson Group, told Fortune, “Watson can summarize that data and incorporate nurse and doctor’s notes to give a more complete picture.”
Related: IBM is bringing sports into the digital age, starting with the U.S. Open.
And Can We Use Them To Improve Health and Longevity
Junk DNA may play a critical role in the creation of new DNA.
